2023 Q2 Form 10-Q Financial Statement
#000121390023038533 Filed on May 11, 2023
Income Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $12.29M | $12.29M | $13.28M |
YoY Change | -15.84% | -7.47% | 58.53% |
% of Gross Profit | |||
Research & Development | $13.74M | $15.86M | $25.01M |
YoY Change | -55.55% | -36.59% | 78.41% |
% of Gross Profit | |||
Depreciation & Amortization | $0.00 | $0.00 | |
YoY Change | |||
% of Gross Profit | |||
Operating Expenses | $26.03M | $28.15M | $38.30M |
YoY Change | -42.81% | -26.49% | 70.89% |
Operating Profit | -$26.03M | -$28.15M | |
YoY Change | -42.81% | ||
Interest Expense | $723.8K | $1.832M | -$1.448M |
YoY Change | -193.45% | -226.49% | -862.29% |
% of Operating Profit | |||
Other Income/Expense, Net | $723.8K | $1.832M | |
YoY Change | -87.02% | ||
Pretax Income | -$25.30M | -$26.32M | -$39.75M |
YoY Change | -36.64% | -33.78% | 78.87% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$25.30M | -$26.32M | -$39.75M |
YoY Change | -36.64% | -33.78% | 78.91% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | -$0.84 | -$0.87 | |
Diluted Earnings Per Share | -$0.84 | -$0.88 | -$1.400M |
COMMON SHARES | |||
Basic Shares Outstanding | 30.10M shares | 30.10M shares | |
Diluted Shares Outstanding | 30.10M shares | 30.10M shares |
Balance Sheet
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $118.5M | $132.4M | $220.6M |
YoY Change | -44.08% | -39.98% | 114.85% |
Cash & Equivalents | $14.47M | $28.89M | $44.93M |
Short-Term Investments | $104.1M | $103.5M | $175.7M |
Other Short-Term Assets | $3.475M | $3.090M | $5.064M |
YoY Change | 1256.23% | -38.99% | 406.4% |
Inventory | |||
Prepaid Expenses | $3.475M | $3.090M | |
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $122.0M | $135.5M | $225.8M |
YoY Change | -43.45% | -39.97% | 117.51% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | |||
YoY Change | |||
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $34.59K | $34.88K | $28.29K |
YoY Change | -1.84% | 23.28% | |
Total Long-Term Assets | $34.59K | $34.88K | $28.29K |
YoY Change | -1.84% | 23.28% | -71.71% |
TOTAL ASSETS | |||
Total Short-Term Assets | $122.0M | $135.5M | $225.8M |
Total Long-Term Assets | $34.59K | $34.88K | $28.29K |
Total Assets | $122.0M | $135.6M | $225.8M |
YoY Change | -43.44% | -39.96% | 117.33% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $4.854M | $4.422M | $10.67M |
YoY Change | -35.63% | -58.56% | 31.73% |
Accrued Expenses | $5.849M | $5.675M | $4.739M |
YoY Change | -48.61% | 19.75% | 3.03% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $10.70M | $10.10M | $15.41M |
YoY Change | -43.44% | -34.47% | 21.33% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | |||
YoY Change | |||
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
YoY Change | |||
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $10.70M | $10.10M | $15.41M |
Total Long-Term Liabilities | $0.00 | $0.00 | $0.00 |
Total Liabilities | $10.70M | $10.10M | $15.41M |
YoY Change | -43.44% | -34.47% | 21.33% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$513.7M | -$488.4M | |
YoY Change | 33.53% | ||
Common Stock | $30.10K | $30.10K | |
YoY Change | 0.25% | ||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $111.3M | $125.5M | $210.4M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $122.0M | $135.6M | $225.8M |
YoY Change | -43.44% | -39.96% | 117.33% |
Cashflow Statement
Concept | 2023 Q2 | 2023 Q1 | 2022 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$25.30M | -$26.32M | -$39.75M |
YoY Change | -36.64% | -33.78% | 78.91% |
Depreciation, Depletion And Amortization | $0.00 | $0.00 | |
YoY Change | |||
Cash From Operating Activities | -$13.27M | -$16.51M | -$19.43M |
YoY Change | -38.62% | -15.05% | 20.76% |
INVESTING ACTIVITIES | |||
Capital Expenditures | |||
YoY Change | |||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$1.152M | $40.00M | -$10.03M |
YoY Change | 719.63% | -498.93% | -164.82% |
Cash From Investing Activities | -$1.152M | $40.00M | -$10.03M |
YoY Change | 719.63% | -498.93% | -164.82% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 29.95M | |
YoY Change | -100.0% | 1451.73% | |
NET CHANGE | |||
Cash From Operating Activities | -13.27M | -$16.51M | -19.43M |
Cash From Investing Activities | -1.152M | $40.00M | -10.03M |
Cash From Financing Activities | 0.000 | 29.95M | |
Net Change In Cash | -14.43M | $23.50M | 490.9K |
YoY Change | 87.98% | 4686.42% | -62.52% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$13.27M | -$16.51M | -$19.43M |
Capital Expenditures | |||
Free Cash Flow | |||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2023Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2023Q1 | dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | |
CY2023Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2023-03-31 | |
CY2023Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2023 | |
CY2023Q1 | dei |
Document Transition Report
DocumentTransitionReport
|
false | |
CY2023Q1 | dei |
Entity File Number
EntityFileNumber
|
000-55347 | |
CY2023Q1 | dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
NV | |
CY2023Q1 | dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
45-5401931 | |
CY2023Q1 | dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
2222 Ponce de Leon | |
CY2023Q1 | dei |
Entity Address Address Line2
EntityAddressAddressLine2
|
Floor 3 | |
CY2023Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
Coral Gables | |
CY2023Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
FL | |
CY2023Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
33134 | |
CY2023Q1 | dei |
City Area Code
CityAreaCode
|
(786) | |
CY2023Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
629-1376 | |
CY2023Q1 | dei |
Security12b Title
Security12bTitle
|
Common stock, $0.001 par value per share | |
CY2023Q1 | dei |
Trading Symbol
TradingSymbol
|
RLMD | |
CY2023Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-488432511 | usd |
CY2023Q1 | dei |
Security Exchange Name
SecurityExchangeName
|
NASDAQ | |
CY2023Q1 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2023Q1 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
CY2023Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
CY2023Q1 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
CY2023Q1 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
CY2023Q1 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2023Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
30099203 | shares |
CY2023Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28894360 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5395905 | usd |
CY2023Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
103547634 | usd |
CY2022Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
142926781 | usd |
CY2022Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
512432 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
3089580 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
4035186 | usd |
CY2023Q1 | us-gaap |
Assets Current
AssetsCurrent
|
135531574 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
152870304 | usd |
CY2023Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
34875 | usd |
CY2022Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
34875 | usd |
CY2023Q1 | us-gaap |
Assets
Assets
|
135566449 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
152905179 | usd |
CY2023Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
4421965 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
5261936 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5675292 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
7206941 | usd |
CY2023Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
10097257 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
12468877 | usd |
CY2023Q1 | us-gaap |
Liabilities
Liabilities
|
10097257 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
12468877 | usd |
CY2023Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3500000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
3500000 | shares |
CY2023Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2023Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30099203 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30099203 | shares |
CY2023Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30099203 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30099203 | shares |
CY2023Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
30099 | usd |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
30099 | usd |
CY2023Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
613871604 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
602517138 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-462110935 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
125469192 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
140436302 | usd |
CY2023Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
135566449 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
152905179 | usd |
CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
15861010 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
25012853 | usd |
CY2023Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12292599 | usd |
CY2022 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
13284570 | usd |
CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
28153609 | usd |
CY2022 | us-gaap |
Operating Expenses
OperatingExpenses
|
38297423 | usd |
CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-28153609 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-38297423 | usd |
CY2023Q1 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
1207631 | usd |
CY2022 | us-gaap |
Interest Income Expense Net
InterestIncomeExpenseNet
|
329949 | usd |
CY2023Q1 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
-666708 | usd |
CY2022 | us-gaap |
Realized Investment Gains Losses
RealizedInvestmentGainsLosses
|
-15022 | usd |
CY2023Q1 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
1291110 | usd |
CY2022 | us-gaap |
Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
|
-1763287 | usd |
CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1832033 | usd |
CY2022 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-1448360 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26321576 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-39745783 | usd |
CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.87 | |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.4 | |
CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
30099203 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
28392601 | shares |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
140436302 | usd |
CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
11354466 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26321576 | usd |
CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
125469192 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
208264886 | usd |
CY2022Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
11930681 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
|
29583542 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
300006 | usd |
CY2022Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
64800 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-39745783 | usd |
CY2022Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
210398132 | usd |
CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26321576 | usd |
CY2022Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-39745783 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11354466 | usd |
CY2022Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
11930681 | usd |
CY2023Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-666708 | usd |
CY2022Q1 | us-gaap |
Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
|
-15022 | usd |
CY2023Q1 | rlmd |
Unrealizeds Lossgain On Shortterm Investments
UnrealizedsLossgainOnShorttermInvestments
|
1291110 | usd |
CY2022Q1 | rlmd |
Unrealizeds Lossgain On Shortterm Investments
UnrealizedsLossgainOnShorttermInvestments
|
-1763287 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
|
-20923 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-512432 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-945606 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-6237575 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
12487917 | shares |
CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-839971 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-522353 | usd |
CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1531649 | usd |
CY2022Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
870905 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16505094 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19429743 | usd |
CY2023Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
34767287 | usd |
CY2022Q1 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
25915957 | usd |
CY2023Q1 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
74770836 | usd |
CY2022Q1 | us-gaap |
Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
|
15888289 | usd |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
40003549 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-10027668 | usd |
CY2022Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
29583542 | usd |
CY2022Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
64800 | usd |
CY2022Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
300006 | usd |
CY2022Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
29948348 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
23498455 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
490937 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
5395905 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
44443439 | usd |
CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
28894360 | usd |
CY2022Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
44934376 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
17.35 | |
CY2023Q1 | rlmd |
Operating Cash Flows
OperatingCashFlows
|
16505094 | usd |
CY2023Q1 | us-gaap |
Retained Earnings Appropriated
RetainedEarningsAppropriated
|
488432511 | usd |
CY2023Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.55in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the reporting period. Actual results could differ from those estimates. The significant estimates are stock-based compensation expenses and recorded amounts related to income taxes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> | |
CY2023Q1 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
28894360 | usd |
CY2023Q1 | us-gaap |
Shortterm Debt Fair Value
ShorttermDebtFairValue
|
103547634 | usd |
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P8Y6M | |
CY2023Q1 | us-gaap |
Short Term Investments
ShortTermInvestments
|
103547634 | usd |
CY2023Q1 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
1291110 | usd |
CY2022 | us-gaap |
Interest And Other Income
InterestAndOtherIncome
|
1763287 | usd |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
417998000000 | usd |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
|
620000 | shares |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.6 | |
CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
15515358 | shares |
CY2022Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13437627 | shares |
CY2023Q1 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
211700 | usd |
CY2022Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
313200 | usd |
CY2023Q1 | rlmd |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
2589800 | usd |
CY2022Q4 | rlmd |
Prepaid Research And Development
PrepaidResearchAndDevelopment
|
3619800 | usd |
CY2023Q1 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
288100 | usd |
CY2022Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
102200 | usd |
CY2023Q1 | us-gaap |
Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
|
3089600 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
|
4035200 | usd |
CY2023Q1 | rlmd |
Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
|
P9Y9M14D | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
93750 | shares |
CY2023Q1 | rlmd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
4806000 | usd |
CY2022Q4 | rlmd |
Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
|
5809800 | usd |
CY2023Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
125000 | usd |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
116500 | usd |
CY2023Q1 | us-gaap |
Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
|
331000 | usd |
CY2022Q4 | us-gaap |
Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
|
492100 | usd |
CY2023Q1 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
332400 | usd |
CY2022Q4 | us-gaap |
Accrued Vacation Current
AccruedVacationCurrent
|
529800 | usd |
CY2023Q1 | us-gaap |
Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
|
80900 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
|
258700 | usd |
CY2023Q1 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
5675300 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
7206900 | usd |
CY2022Q2 | us-gaap |
Other Partners Capital
OtherPartnersCapital
|
100000000 | usd |
CY2014Q4 | rlmd |
Granting To Option Or Stock Awards
GrantingToOptionOrStockAwards
|
5152942 | shares |
CY2021Q2 | rlmd |
Granted Options
GrantedOptions
|
1500000 | shares |
CY2022Q2 | rlmd |
Granted Options
GrantedOptions
|
3900000 | shares |
CY2022Q2 | rlmd |
Granting To Option Or Stock Awards
GrantingToOptionOrStockAwards
|
10552942 | shares |
CY2023Q1 | rlmd |
Stock Options Exercisable Period
StockOptionsExercisablePeriod
|
P10Y | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P4Y | |
CY2023Q1 | us-gaap |
Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
|
1934975 | shares |
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y3M | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.156 | pure |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Other Description
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOtherDescription
|
the Company has unrecognized stock-based compensation expense of approximately $84.5 million related to unvested stock options which will be recognized over the weighted average remaining service period of 2.62 years. | |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
12122606 | shares |
CY2022Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
18.19 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
160939 | shares |
CY2023Q1 | rlmd |
Weighted Average Remaining Contractual Term Years Ending Balance1
WeightedAverageRemainingContractualTermYearsEndingBalance1
|
P8Y3M29D | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
4774660 | shares |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
21.33 | |
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y5M15D | |
CY2022Q4 | rlmd |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
|
3027441 | shares |
CY2022Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
17.02 | |
CY2023Q1 | rlmd |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber1
|
3027441 | shares |
CY2023Q1 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
17.02 | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
2798566 | shares |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
15.75 | |
CY2023Q1 | rlmd |
Unrecognized Compensation Expense
UnrecognizedCompensationExpense
|
5.5 | |
CY2023Q1 | rlmd |
Intrinsic Value Of Warrant Vested And Outstanding
IntrinsicValueOfWarrantVestedAndOutstanding
|
0 | |
CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11354500 | usd |
CY2022Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
11930700 | usd |
CY2023Q1 | us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
180000 | usd |
CY2023Q1 | rlmd |
Payment For License
PaymentForLicense
|
45000 | usd |
CY2022Q1 | rlmd |
Payment For License
PaymentForLicense
|
45000 | usd |
CY2023Q1 | rlmd |
Fee Amount
FeeAmount
|
12700000 | usd |
CY2023Q1 | us-gaap |
Short Term Lease Payments
ShortTermLeasePayments
|
160000000 | usd |
CY2021Q3 | us-gaap |
Payments For Rent
PaymentsForRent
|
11000 | usd |
CY2021Q3 | rlmd |
Lease Period
LeasePeriod
|
P5M | |
CY2023Q1 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2021-12-31 | |
CY2022 | us-gaap |
Payments For Rent
PaymentsForRent
|
9000 | usd |
CY2023Q1 | us-gaap |
Payments For Rent
PaymentsForRent
|
15000 | usd |
CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
51700 | usd |
CY2022Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
19500 | usd |
CY2017Q2 | us-gaap |
Direct Taxes And Licenses Costs
DirectTaxesAndLicensesCosts
|
7529 | usd |
CY2023Q1 | us-gaap |
Other Assets
OtherAssets
|
493452 | usd |
CY2023Q1 | us-gaap |
Operating Lease Lease Income Lease Payments
OperatingLeaseLeaseIncomeLeasePayments
|
397049 | usd |
CY2023Q1 | us-gaap |
Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
|
0.0838 | pure |
CY2023Q1 | us-gaap |
Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
|
96403 | usd |
CY2022Q1 | us-gaap |
Unearned Premiums
UnearnedPremiums
|
2300 | usd |
CY2023Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2023Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001553643 | |
CY2023Q1 | us-gaap |
Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
|
The Company matches 100% of the first 3% of employee contributions, plus 50% of employee contributions that exceed 3% but do not exceed 5%. | |
CY2023Q1 | rlmd |
Employee Contribution Expense
EmployeeContributionExpense
|
40400 | usd |
CY2022Q1 | rlmd |
Employee Contribution Expense
EmployeeContributionExpense
|
31600 | usd |
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
|
15000 | shares |
CY2023Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
RELMADA THERAPEUTICS, INC. | |
CY2023Q1 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
usd | |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
28392601 | shares |
CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
30099203 | shares |
CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
usd | |
CY2022Q1 | us-gaap |
Depreciation
Depreciation
|
usd | |
CY2023Q1 | us-gaap |
Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
|
usd | |
CY2022Q1 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
usd | |
CY2023Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
usd | |
CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
usd | |
CY2023Q1 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
usd | |
CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
usd | |
CY2023Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
CY2022Q1 | us-gaap |
Income Taxes Paid Net
IncomeTaxesPaidNet
|
usd | |
CY2023Q1 | us-gaap |
Interest Paid
InterestPaid
|
usd | |
CY2022Q1 | us-gaap |
Interest Paid
InterestPaid
|
usd | |
CY2023Q1 | rlmd |
Aggregate Intrinsic Value Outstanding And Expected To Vest Granted1
AggregateIntrinsicValueOutstandingAndExpectedToVestGranted1
|
usd | |
CY2023Q1 | rlmd |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm1
|
||
CY2023Q1 | rlmd |
Aggregate Intrinsic Value Outstanding And Expected To Vest Forfeited1
AggregateIntrinsicValueOutstandingAndExpectedToVestForfeited1
|
usd | |
CY2022 | rlmd |
Weighted Average Remaining Contractual Term Years Cancelled
WeightedAverageRemainingContractualTermYearsCancelled
|
||
CY2022 | rlmd |
Aggregate Intrinsic Value Cancelled
AggregateIntrinsicValueCancelled
|
usd | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
|
shares | |
CY2023Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
|
||
CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
|
shares | |
CY2023Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
||
CY2023Q1 | us-gaap |
Unearned Premiums
UnearnedPremiums
|
usd | |
CY2023Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2023Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 |